The cardiovascular benefits of GLP1 RAs have been well characterized in several large cardiovascular outcome trials. The benefits of secondary kidney outcomes in those with diabetes have been observed in these trials. In this module, we will review current evidence supporting the benefits of GLP-1 RAs in the patients with kidney disease. We will also review current clinical guidelines and recommendations for their use and discuss medication and patient-specific efficacy and safety considerations when using them in people with type 2 diabetes and chronic kidney disease.
Joshua J. Neumiller, PharmD, CDCES, FASCES, FASCP
Vice-Chair and Allen I. White Distinguished Professor of Pharmacotherapy, Washington State University
Dr. Joshua J. Neumiller is Vice-Chair and Allen I. White Distinguished Professor in the Department of Pharmacotherapy at Washington State University. Dr. Neumiller is past Chair of the American Diabetes Association's (ADA's) Professional Practice Committee whose primary responsibility is revising the ADA Standards of Medical Care in Diabetes each year, and is also a co-author for the 2022 ADA/KDIGO consensus on Diabetes Management in CKD. Josh works clinically as a consultant pharmacist in the home care setting and specializes in managing people with diabetes and kidney disease.
